ArticleNature2024
An atlas of epithelial cell states and plasticity in lung adenocarcinoma.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 125 papers.
0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed
39.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 141 citations in OpenAlex.
- Quercetin-derived carbon dots-modified ZIF-8 and M2 macrophage-derived migrasomes-functionalized microenvironment-responsive nanocomposite hydrogel for osteoporotic bone defects regeneration.Bioactive materials · 2027Article
- Genes, fuel, and fate in lung cancer.Biochemical Society transactions · 2026Review
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- The CRABP2-MDK Signaling Axis Promotes Lung Adenocarcinoma (LUAD) Progression and Highlights Prognostic Biomarkers.Molecular carcinogenesis · 2026Article
- Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8Cell reports. Medicine · 2026Article
- Plasma biomarkers predicting development of lung cancer 5 years before diagnosis.Journal of hematology & oncology · 2026Article
- Evolving patterns of co-mutations from tumor initiation to metastatic progression.Nature genetics · 2026Article
- Integrated multi-omics and single-cell analyses identify metabolic heterogeneity and therapeutic vulnerabilities in medullary thyroid cancer.British journal of cancer · 2026Article
- Identifying Epithelial-Cell Progression Signatures (ECPSs) from Multi-Resolution Multi-Omics Data for Translational Clinical Applications in Lung Adenocarcinoma.International journal of molecular sciences · 2026Article
- The AGO2 adaptor LIMD1 expands the functional and evolutionary reach of microRNA targeting.Science advances · 2026Article
- Single-cell multimodal profiling of pan-cancer cell lines uncovers gene regulatory principles underlying intrinsic cell states and environmental features.Nature communications · 2026Article
- Neural crest cell signatures drive tumorigenesis in tuberous sclerosis complex and lymphangioleiomyomatosis.JCI insight · 2026Article
- Statescope: an integrative deconvolution framework for discovering cell states in tumors.Nature communications · 2026Article
- Transitional cell states at the crossroads of development, disease, and repair-regeneration.Physiological reviews · 2026Review
- Integrated stress response couples mitochondrial fitness with lineage reprogramming to drive cancer evolution.Nature cell biology · 2026Article
- HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.The Journal of clinical investigation · 2026Article
- Single-cell-marker-based subtyping and multi-level analyses uncover the prognostic effects, dysregulations and therapeutic indicative potential of an eight-gene signature in lung adenocarcinoma.Cancer cell international · 2026Article
- Microbiome-host interactions in different pathomic subtypes of early-stage lung adenocarcinoma.BMC pulmonary medicine · 2026Article
- Article
- Condition-Associated Pattern Extraction and Recovery From Multi-Condition Single-Cell RNA-seq Data With CAPER.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
38 authors at 5 institutions in 1 country.
Guangchun Han *Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9277-2507
Ansam Sinjab *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5777-227X
Zahraa Rahal *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anne M Lynch *Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Warapen TreekitkarnmongkolDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7542-5201
Yuejiang LiuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1432-3938
Alejandra G SerranoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jiping FengDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ke LiangDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Khaja KhanDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei LuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sharia D HernandezDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yunhe LiuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2120-952X
Xuanye CaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2181-3540
Enyu DaiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guangsheng PeiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jian HuDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Camille AbayaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lorena I Gomez-BolanosDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5132-4417
Fuduan PengDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Minyue ChenDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5721-5107
Edwin R ParraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9068-1636
Tina CasconeDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3008-5407
Boris SepesiDepartment of Cardiovascular and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1442-611X
Seyed Javad MoghaddamDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5350-307X
Paul ScheetDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5173-7497
Marcelo V NegraoDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8938-6699
John V HeymachDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9068-8942
Mingyao LiDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8180-0621
Steven M DubinettDepartment of Medicine, The University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-3656-8039
Christopher S StevensonLung Cancer Initiative at Johnson & Johnson, Boston, MA, USA.
Avrum E SpiraLung Cancer Initiative at Johnson & Johnson, Boston, MA, USA.
Junya FujimotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4813-3163
Luisa M SolisDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1253-630X
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jichao ChenDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. JChen16@mdanderson.org.ORCID 0000-0003-2749-8550
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lwang22@mdanderson.org.ORCID 0000-0001-9380-0266
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hkadara@mdanderson.org.ORCID 0000-0003-2976-9115
The University of Texas MD Anderson Cancer Center · USUniversity of Pennsylvania · USBoston University · USJohnson & Johnson (United States) · USUniversity of California, Los Angeles · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MThe Lung PCA: A Multi-Dimensional Atlas of Pulmonary PremalignancyU2CCA233238 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SPIRA, AVRUM E · 2018 to 2021
$7.0MRole of AT1 cells in perinatal lung maturationR01HL130129 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, JICHAO · 2016 to 2023
$4.1MTranscriptional and epigenetic mechanisms of alveologenesis and re-alveologenesisR35HL171346 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Jichao Chen · 2024 to 2026
$3.3MElucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancerR01CA272863 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Humam Kadara, Seyed Javad Mirhassani Moghaddam · 2022 to 2026
$2.9MTranscriptional and epigenetic basis of lung epithelial cell fateR01HL153511 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, JICHAO · 2020 to 2023
$2.5MTranslational Genomics and Precision Medicine in Cancer Training ProgramT32CA217789 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Subrata Sen · 2018 to 2026
$2.2MSpatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma developmentU01CA264583 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Humam Kadara, Linghua Wang · 2022 to 2026
$2.1M(PQ1) Progression of the airway field of injury to Kras mutant lung cancerR01CA205608 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KADARA, HUMAM, SCHEET, PAUL A · 2016 to 2019
$1.4MNovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995kAP-1 as a transcriptional regulator of AT2 cell reversible activation during lung injury responseF31HL165914 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI LYNCH, ANNE · 2022 to 2024
$143kNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA205608NCI NIH HHS R01 CA272863NCI NIH HHS T32 CA217789NCI NIH HHS U01 CA264583NCI NIH HHS U2C CA233238NHLBI NIH HHS F31 HL165914NHLBI NIH HHS R01 HL130129NHLBI NIH HHS R01 HL153511NHLBI NIH HHS R35 HL171346NIH HHS S10 OD024977
Abstract
Understanding the cellular processes that underlie early lung adenocarcinoma (LUAD) development is needed to devise intervention strategies
Indexed as
Adenocarcinoma of LungCell DifferentiationEpithelial CellsLung NeoplasmsAlveolar Epithelial CellsAneuploidyAnimalsCarcinogensHumansKeratin-8MiceMutationOrganoidsPrecancerous ConditionsProto-Oncogene Proteins p21(ras)Survival RateCarcinogensHras protein, mouseKeratin-8KRAS protein, humanKRT8 protein, humanKrt8 protein, mouseProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.